Glucocorticoids influence a wide range of metabolic processes in the human body, and excessive glucocorticoid exposure is known to contribute to the development of metabolic disease. We evaluated the utility of the novel glucocorticoid receptor (GR) antagonist CORT125281 for its potential to overcome adiposity, glucose intolerance, and dyslipidemia and compared this head-tohead with the classic GR antagonist RU486 (mifepristone). We show that, although RU486 displays cross-reactivity to the progesterone and androgen receptor, CORT125281 selectively inhibits GR transcriptional activity. In a mouse model for diet-induced obesity, rhythmicity of circulating corticosterone levels was disturbed. CORT125281 restored this disturbed rhythmicity, in contrast to RU486, which further inhibited endogenous corticosterone levels and suppressed adrenal weight. Both CORT125281 and RU486 reduced body weight gain and fat mass. In addition, CORT125281, but not RU486, lowered plasma levels of triglycerides, cholesterol, and free fatty acids and strongly stimulated triglyceride-derived fatty acid uptake by brown adipose tissue depots. In combination with reduced lipid content in brown adipocytes, this indicates that CORT125281 enhances metabolic activity of brown adipose tissue depots. CORT125281 was also found to increase liver lipid accumulation. Taken together, CORT125281 displayed a wide range of beneficial metabolic activities that are in part distinct from RU486, but clinical utility may be limited due to liver lipid accumulation. This warrants further evaluation of GR antagonists or selective modulators that are not accompanied by liver lipid accumulation while preserving their beneficial metabolic activities. (Endocrinology 159: 535-546, 2018) O besity and dyslipidemia constitute major problems in modern society (1, 2), and it is increasingly being recognized that glucocorticoid (GC) stress hormones contribute to such metabolic abnormalities (3). GCs are produced in the adrenal cortex and bind to the glucocorticoid receptor (GR) or the mineralocorticoid receptor (MR), thereby regulating a wide range of processes in the human body, including lipid and glucose mobilization and disposal. Circulating GC levels display a diurnal rhythmicity, and GCs are released in response to stress.
O besity and dyslipidemia constitute major problems in modern society (1, 2) , and it is increasingly being recognized that glucocorticoid (GC) stress hormones contribute to such metabolic abnormalities (3) . GCs are produced in the adrenal cortex and bind to the glucocorticoid receptor (GR) or the mineralocorticoid receptor (MR), thereby regulating a wide range of processes in the human body, including lipid and glucose mobilization and disposal. Circulating GC levels display a diurnal rhythmicity, and GCs are released in response to stress.
Hypothalamic-pituitary-adrenal (HPA) axis activity regulates GC secretion by a cascade of hormonal processes, initiated by release of corticotropin-releasing hormone and vasopressin by the paraventricular nucleus of the hypothalamus, which results in secretion of adrenocorticotropic hormone (ACTH) by the anterior pituitary. ACTH subsequently stimulates GC production and secretion by the adrenals. HPA axis activity is controlled by GC-mediated negative feedback on multiple levels including the inhibition of ACTH release (4, 5) .
Hyperactivity of the HPA axis (e.g., in Cushing syndrome) causes a myriad of metabolic adverse effects, and GR antagonists were shown to be effective in counteracting this (6) . Despite being extensively used in the clinic, GR antagonist RU486 (mifepristone) lacks receptor selectivity (7) and may in certain settings also exhibit partial agonist activity (8) . Therefore, the use of a selective GR antagonist that lacks partial agonistic properties may be of value.
Brown adipose tissue (BAT) is a relevant metabolic target tissue of GC that has been actively pursued to combat obesity and related disorders after its discovery in humans (9) . BAT effectively combusts glucose and fatty acids into heat, contributing to energy expenditure (10) . BAT is activated by cold via enhanced sympathetic outflow. The norepinephrine (NE) released from sympathetic nerve terminals binds to the b3-adrenergic receptor on brown adipocytes and strongly enhances activity and expression of uncoupling protein 1 (UCP-1), the main effector protein involved in thermogenesis (11) . Therapeutic targeting of BAT (e.g., with a b3-adrenergic receptor agonist) may provide an effective strategy to improve metabolic health, as it alleviates dyslipidemia, lowers blood glucose, prevents weight gain, and protects from atherosclerosis development in mice (12, 13) . Accumulating evidence indicates that chronic exposure to elevated endogenous GC (14, 15) or synthetic GR agonists (16) inhibits the activity of brown adipocytes and hampers the browning of white adipose tissue (WAT) (17) , although acute effects may differ between mouse and man (18) . Vice versa, the classic GR antagonist RU486 was shown to acutely stimulate BAT activity (8, 15, 19) .
In this study, we characterized novel GR antagonist CORT125281 (20) and evaluated its effects on energy metabolism and lipid distribution in male C57BL/6J mice fed a high-fat diet (HFD). CORT125281 effectively inhibited GR activity in several cell culture models, whereas MR, progesterone receptor (PR), and androgen receptor (AR) activity was unaffected. CORT125281 inhibited weight gain and lowered plasma lipids in a model for diet-induced obesity, accompanied by robust activation of BAT in comparison with RU486. CORT125281 adversely affected hepatic lipid metabolism in mice, warranting further search for selective GR modulators that efficiently antagonize GR in BAT without adversely affecting the liver.
Materials and Methods

Animals
All animal studies reported here have been approved by the ethical committee of Leiden University Medical Center. Mice were housed in conventional cages with a 12:12-hour light-dark cycle with ad libitum access to food and water. Ten-week-old male C57BL/6J mice (Jackson Laboratory, Bar Harbor, ME) were fed a control chow diet vs chow diet supplemented with CORT125281 (60 mg/kg/d) for 3 weeks (n = 8 per group); received water containing 10% fructose in combination with an HFD (60% lard, Research Diets) supplemented with vehicle, CORT125281 (60 mg/kg/d), or RU486 (also known as mifepristone; 60 mg/kg/d) for 3 weeks (n = 8 per group); or were treated with different dosages of CORT125281 by diet supplementation (6, 20, or 60 mg/kg/d) for 3 weeks (n = 7 to 8 per group).
Body weight, body composition, and indirect calorimetry measurements Body weight and composition (EchoMRI-100, Houston, TX) were determined throughout all experiments. Indirect calorimetry was performed in fully automatic metabolic cages (LabMaster System; TSE Systems, Bad Homburg, Germany) from day 1 until day 6. Oxygen consumption, carbohydrate production, and caloric intake were measured and used to calculate energy expenditure and fat and carbohydrate oxidation (21).
Stress-free blood collection and corticosterone measurement
Stress-free blood samples (i.e., drawn within 2 minutes before plasma corticosterone levels rise) were collected after 13 days in the morning (8:30, zeitgeber time 1.5) and evening (17:30, zeitgeber time 10.5), and corticosterone levels were determined using a 125 I radioimmunoassay kit (ImmuChem; MP Biochemicals, Orangeburg, NY).
Plasma lipid determination
After 3 weeks of treatment, blood was collected from 4-hour fasted mice to determine plasma triglycerides (TGs), plasma total cholesterol (both with enzymatic kits from Roche Diagnostics, Mannheim, Germany), and plasma free fatty acids (FFAs) (NEFA C kit; Wako Diagnostics, Instruchemie, Delfzijl, The Netherlands).
Intravenous glucose tolerance test
After 2 weeks, a glucose tolerance test was performed. Mice were fasted for 6 hours, and at t = 0 minutes, blood was collected. After this, mice were intravenously injected with glucose (2 g/kg), and blood was collected at t = 5, 15, 30, 60, and 120 minutes. In all samples, plasma glucose was measured using an enzymatic kit (Instruchemie).
TG clearance experiment
At the end of the experiment, the clearance of TGs was determined. Glycerol tri[ were injected intravenously in the tail vein of the mice, and blood was collected at t = 2, 5, 10, and 15 minutes (22) . Mice were euthanized by cervical dislocation directly after the last blood sample and perfused with ice-cold phosphatebuffered saline for 5 minutes, and organs were harvested, weighted, and divided in pieces for messenger RNA analysis, histology, or analysis of 3 H activity.
Histology
Metabolic organs [i.e., interscapular BAT (iBAT), gonadal WAT, and liver] were fixated in 4% paraformaldehyde for 1 day and stored in 70% ethanol until further processing. Tissues were dehydrated and embedded in paraffin, and 5-mm sections were stained for hematoxylin-eosin and Oil Red O as previously described (23) . Intracellular lipid droplet size and lipid content were quantified using Image J software (version 1.47).
Cell culture HEK293T cells
Human HEK293T cells were transfected using Fugene HD transfection reagent (Promega, Leiden, the Netherlands) with 25 ng TAT3-luciferase (TAT3-luc), 1 ng CAGGS-renilla, 100 ng pcDNA, and 10 ng human GR, MR, AR, or PR expression vector. Cells were pretreated with different concentrations of RU486 or CORT125281 for 1 hour before exposure to 50 nM cortisol (= hydrocorticosone) (for GR, 74-fold induction of GR signaling, data not shown), 10 nM cortisol (for MR, sixfold induction of MR signaling, data not shown), 10 nM progesterone (for PR, sixfold induction of PR signaling, data not shown), or 100 nM dihydrotestosterone (DHT) (for AR, fourfold induction of AR signaling, data not shown). After 24 hours, firefly and renilla luciferase signals were measured using a Dual Luciferase assay (Promega).
Cell culture murine brown adipocytes
Brown preadipocytes from murine BAT depots were isolated from 5-week-old male C57BL6/J mice. Cells were reversibly immortalized by using a lentiviral vector conferring doxycylin-controlled expression of simian virus large T antigen and expanded in maintenance medium (Dulbecco's modified Eagle medium/F12 medium supplemented with heatinactivated fetal bovine serum, 4.5 g/L glucose, penicillin/ streptomycin, and 0.1 mg/mL doxycycline). Adipogenic differentiation was induced by culturing the cells for 13 to 15 days in differentiation medium (Dulbecco's modified Eagle medium/F12 supplemented with 4.5 g/L glucose, 10% heatinactivated fetal bovine serum, penicillin/streptomycin, 4 nM bovine insulin, 10 mM HEPES, 25 mg/mL ascorbate, and 1 mM rosiglitazone). During the last 2 days of differentiation and during the experiments, GC-free charcoal-stripped serum was used and the effects on GR transcriptional activity and BAT activity were examined in fully differentiated brown adipocytes. BAT activity was stimulated with 1 mM NE, and cells were simultaneously exposed to a combination of 10 to 1000 nM corticosterone, 10 to 1000 nM CORT125281, and/or 10 to 1000 nM RU486. After an incubation period of 8 hours, cells were lysed using TriPure (Roche, Mijdrecht, the Netherlands).
RNA isolation, complementary DNA synthesis, and reverse transcription polymerase chain reaction analysis Total RNA was isolated using TriPure (Roche) according to the manufacturer's protocol, and 500 to 1000 ng RNA was reverse-transcribed using M-MLV reverse-transcriptase (Promega). Reverse transcription polymerase chain reaction was performed on a CFX96 PCR machine using IQ SYBRGreen (Bio-Rad, Veenendaal, the Netherlands), and expression levels were normalized to housekeeping genes b2-microglobulin (B2M) or 36B4. Primer sequences are shown in Supplemental Table 1 .
Statistical analysis
All data are presented as mean 6 standard error of the mean. Statistical analyses were performed with GraphPad Prism 7 software (GraphPad Inc., La Jolla, CA), and for mixed-model analysis, IBM SPSS 23 software was used. Statistical differences were calculated with a one-way analysis of variance with the Tukey multiple-comparison test, with a two-way analysis of variance with the Tukey multiple-comparison test, with a linear mixed model with time as the covariate, or with an unpaired t test, as appropriate. P , 0.05 was considered significant for all analyses. IC 50 values were calculated using GraphPad Prism 7 software, using a nonlinear fit model.
Results
CORT125281 selectively inhibits GR whereas RU486 exhibits cross-reactivity for PR and AR
The effect of the novel GR antagonist CORT125281 on GR transcriptional activity was examined and compared with classic GR antagonist RU486. Human HEK293T cells were transfected with GR and a TAT3-luc reporter, and this revealed the expected inhibition of cortisol-induced GR activity by both GR antagonists (20) , in which RU486 was significantly more potent than CORT125281 (IC 50 of 43 nM and 427 nM, respectively, P , 0.0001) (Fig. 1A) . To investigate receptor selectivity, HEK293T cells were transfected with MR, PR, or AR in combination with TAT3-luc and treated with their respective agonists around their estimated EC 90 concentration (24) . Neither CORT125281 nor RU486 affected cortisol-induced MR signaling (Fig. 1B) . Although RU486 potently inhibited PR signaling (IC 50 : 0.6 nM) (Fig. 1C) and also displayed moderate inhibitory actions on AR signaling (IC 50 : 4.1 mM) (Fig. 1D) , CORT125281 did not affect progesterone-induced PR signaling and DHT-induced AR signaling ( Fig. 1C and 1D ). Taken together, this supports the notion that CORT125281 is a selective GR antagonist, whereas RU486 exhibits crossreactivity for PR and AR.
CORT125281 reverses corticosterone-mediated GR activity in murine brown adipocytes in vitro
To assess whether CORT125281 influences the activity of brown adipocytes, we used cell lines derived from murine BAT depots. Preadipocytes were differentiated into mature brown adipocytes and treated with corticosterone in combination with RU486 or CORT125281. To determine the effect of both compounds on GR transcriptional activity, we measured the expression of the well-known GR target genes Fkbp5 and Gilz (25, 26). Murine brown adipocytes were responsive to corticosterone, as treatment with 10 nM corticosterone significantly upregulated expression of Fkbp5 and Gilz ( Fig. 2A and 2B ). Treatment with either RU486 or CORT125281 effectively inhibited corticosteroneinduced GR transcriptional activity ( Fig. 2A and  2B) . Also, for GR transcriptional activity induced by 1 mM corticosterone, both GR antagonists significantly inhibited GR target gene expression, although GR inhibition by 1 mM RU486 was stronger compared with 1 mM CORT125281, likely reflecting differences in binding affinity (Supplemental Fig. 1A and 1B) (20) . As expected, activity of murine brown adipocytes was inhibited by corticosterone, that is, decreased NE-induced UCP-1 expression upon 10 nM (Fig. 2C ) and 1 mM corticosterone exposure (Supplemental Fig. 1C ). Both CORT125281 and RU486 were able to (partially) prevent corticosteroneinduced inhibition of BAT activity, as coincubation with the GR antagonists results in enhanced UCP-1 expression (Fig. 2C, Supplemental Fig. 1C ). Of note, RU486 did not dose-dependently reverse corticosterone-inhibited UCP-1 expression (Fig. 2C) and was not able, even at high doses, to fully prevent corticosterone-inhibited UCP-1 expression (Supplemental Fig. 1C ). These findings may be explained by partial agonistic properties of RU486 on the GR. To test this, mature brown adipocytes were treated with different doses of RU486 or CORT125281, and this was compared with the agonistic effect of 10 nM corticosterone. Treatment with RU486 resulted in upregulation of the GR target gene Fkbp5 (P , 0.05) but not Gilz, whereas CORT125281 did not influence Fkbp5 or Gilz expression (Fig. 2D) . RU486 treatment tended to reduce NE-induced Ucp1 expression (240% vs vehicle), which is significant compared with 10 nM CORT125281 (P , 0.01, Fig. 2D ). Taken together, these data suggest partial agonistic properties of RU486, which could limit BAT activating capacity by RU486, Figure 1 . The effect of GR antagonists on nuclear receptor signaling in vitro. HEK293T cells transfected with a TAT3-luc reporter were used to determine the antagonistic effects of CORT125281 and RU486 on (A) corticosterone-induced (10 nM) GR signaling, (B) corticosterone-induced (50 nM) MR signaling, (C) progesterone-induced (10 nM) PR signaling, and (D) DHT-induced (100 nM) AR signaling. Statistical significance was calculated using two-way analysis of variance with the Bonferroni multiple-comparisons test. **P , 0.01 vs CORT125281, ****P , 0.0001 vs CORT125281. whereas CORT125281 showed only antagonistic properties on brown adipocytes.
CORT125281 reduces body weight, fat mass, and plasma lipids in HFD-fed mice
To evaluate the effects of CORT125281 on metabolism in a whole organism, a mouse model for dietinduced obesity was used. HFD-fed mice were treated with either CORT125281 (60 mg/kg/d) or the classic GR antagonist RU486 (60 mg/kg/d). For comparison, we also performed an experiment in which chow-fed mice were treated by diet supplementation with CORT125281 (60 mg/kg/d). At equal dosage, CORT125281 and RU486 similarly reduced HFD-induced body weight gain with 10% (P , 0.001 for CORT125281 at day 21, Fig. 3A) , whereas body weight was not altered in chow-fed mice (Supplemental Fig. 2A ). Both GR antagonists significantly reduced fat mass but not lean mass in HFD-fed mice (223% for RU486 and 232% for CORT125281 at day 21, P , 0.01 and P , 0.0001, respectively) ( Fig. 3B  and 3C ), whereas CORT125281 did not affect fat mass or lean mass in chow-fed mice (Supplemental Fig. 2B and  2C ). In the HFD condition, treatment with CORT125281 significantly lowered plasma TGs (256%, P , 0.0001) (Fig. 3D ) and cholesterol levels (230%, P , 0.05) (Fig. 3E ) compared with vehicle and RU486-treated mice, as well as significantly lowered plasma FFAs compared with RU486-treated mice (223%, P , 0.05) (Fig. 3F) . Similar plasma lipid-lowering activities of CORT125281 were found in chowfed mice (i.e., significant reduction of plasma TGs and cholesterol and a near-significant reduction of FFAs) (Supplemental Fig. 2D-2F ). In a subsequent experiment, different dosages of CORT125281 (6, 20, or 60 mg/kg/d) were evaluated in HFD-fed mice, which revealed that CORT125281 seemed to reduce body weight, fat mass, plasma TGs, cholesterol, and FFAs in a dosedependent manner, with no effect on lean mass (Supplemental Fig. 3A-3F ). In addition to lipid metabolism, we investigated the effects of CORT125281 on glucose metabolism. This revealed that CORT125281 did not affect basal glucose levels or intravenous glucose tolerance ( Fig. 3G and 3H ), whereas RU486 significantly improved glucose tolerance in HFD-fed mice, to a similar degree as previously described (27) . Altogether, these data suggest that CORT125281 treatment reduces diet-induced weight gain and body fat mass and that CORT125281 effectively lowers plasma lipids.
CORT125281 restores HFD-disturbed HPA axis activity
Under chow-fed conditions, mice display a circadian rhythm in circulating corticosterone with peak levels before the dark phase (i.e., start of the active period, data not shown). Three weeks of HFD resulted in dampening of the circadian corticosterone rhythm, as morning and evening circulating corticosterone levels were similar (Fig. 4A) . RU486 treatment resulted in lower circulating corticosterone levels in the evening, suggesting an agonistic effect on the HPA axis resulting in enhanced negative feedback under this dose regimen (280%, P , 0.01) (Fig. 4A) . Strikingly, CORT125281 restored the HFD-disturbed circadian corticosterone rhythm (P , 0.0001, morning vs evening), and substantially higher circulating corticosterone levels in the evening were found compared with vehicle HFD-fed mice (P , 0.0001) (Fig. 4A) . The lack of agonistic activity of CORT125281 is further supported by the observation that CORT125281 did not influence adrenal weight, whereas RU486 induced adrenal atrophy (251% organ weight, P , 0.05) (Fig. 4B, Supplemental Fig. 4A ), indicating continuous negative feedback on the HPA axis. At all evaluated dosages, CORT125281 did not influence the weight of the thymus and spleen (Fig. 4C  and 4D , Supplemental Fig. 4B and 4C ), organs that involute after chronic GC exposure, whereas RU486 was found to reduce thymus weight (247%, P , 0.05) (Fig. 4C ).
CORT125281 stimulates fatty acid uptake and combustion by interscapular BAT
To monitor energy expenditure, mice were housed in fully automated metabolic cages during the first week of treatment. RU486 significantly increased total energy expenditure, whereas CORT125281 did not (Fig. 5A) . Treatment with RU486 and CORT125281 both resulted in increased fat oxidation (Fig. 5B) and decreased carbohydrate oxidation (Fig. 5C) , as evident from a lowered respiratory exchange ratio (Fig. 5D) Fig. 5E ), indicating enhanced TG uptake from plasma. Uptake of [
3 H]TOderived activity by iBAT and dorso-cervical BAT was significantly increased in the CORT125281 group (+115%, P , 0.0001 and +61%, P , 0.05, respectively) ( Fig. 5F ), indicating enhanced metabolic activity of these BAT depots. This is further supported by a tendency toward reduced iBAT weight (Fig. 5G, Supplemental Fig. 5A ), accompanied by reduced lipid content in CORT125281-treated mice compared with RU486-treated mice (251%, P , 0.05) (Fig. 5H and 5I ). In addition, CORT125281-and RU486-treated mice showed decreased gonadal WAT weight and smaller average cell size (Fig. 5J-5L , Supplemental Fig. 5B ). Collectively, these data suggest that CORT125281 activated BAT to stimulate fatty acid uptake and combustion, whereas RU486 did not.
CORT125281 increases liver lipid content
As GR activity is known to influence hepatic function (e.g., lipid uptake, very-low-density lipoprotein production, de novo lipogenesis) (14), we next analyzed the livers of mice treated with RU486 and CORT125281. In HFD-fed mice, CORT125281 significantly increased liver weight (+51%, P , 0.01) (Fig. 6A, Supplemental Fig. 5C ) and treatment with CORT125281 was accompanied by increased liver TGs (+88%, P , 0.05) (Supplemental Fig. 5D ) and total liver lipids (visualized by an Oil Red O staining, Fig. 6B  and 6C ). Also, in chow-fed mice, CORT125281 seemed to increase liver weight and significantly increased liver TGs (Supplemental Fig. 2G and  2H ). Of note, both RU486 and CORT125281 strongly upregulated expression of Cyp3a11, suggestive of induction of the pregnane X receptor (PXR) (Fig. 6D) . PXR agonism is known to cause hepatic lipid accumulation, at least partly via increased hepatic expression of fatty acid transporter Cd36 (28), which we also observed for both CORT125281 and RU486 (Fig. 6E) . Although RU486 induced Cyp3a11 expression most strongly, this was not accompanied by the highest hepatic lipid content (Fig. 6B-6E ), suggesting additional, differential effects of RU486 and CORT125281 on liver lipid metabolism.
Discussion
In this study, we describe the effects of a novel GR antagonist CORT125281 on metabolism and HPA axis activity in a model for diet-induced obesity in male mice. In our studies, we compared CORT125281 head-to-head with the classic GR antagonist RU486. First, we characterized the GR specificity of CORT125281, and luciferase reporter experiments clearly show that CORT125281 selectively inhibits the GR, whereas the classic GR antagonist RU486 also inhibits PR and AR transcriptional activity, as expected (7, 29) . In a model for diet-induced obesity, we have shown that CORT125281 and RU486 equally reduce body weight gain in HFD-fed mice, similar to previous observations for RU486 (30) . In addition, both GR antagonists reduce total fat mass without adversely affecting the lean mass. CORT125281, but not RU486, significantly lowered plasma lipids, restored circadian corticosterone rhythmicity, and induced fatty acid uptake and combustion by iBAT. Both GR antagonists effectively reversed corticosterone-suppressed UCP-1 expression in brown adipocytes in vitro, and this reversal of corticosterone-inhibitory actions on BAT could partially underlie the CORT125281-induced BAT activity observed in vivo. Although RU486 may activate BAT in specific contexts (8) , in the present setting, RU486 did not seem to activate BAT in vivo, and this discrepancy between RU486 and CORT125281 may be explained by differential effects on PR or AR activity. Alternatively, because ACTH was shown to stimulate BAT activity (15) , the restored HPA axis activity in CORT125281-treated mice may augment circulating ACTH levels and thereby enhance ACTH-induced BAT activation. The lack of partial agonism on the HPA axis by CORT125281 may thus underlie the differential effects of RU486 and Cd36. Statistical significance was calculated using a one-way analysis of variance with the Tukey multiple-comparisons test. **P , 0.01 vs Veh, ****P , 0.0001 vs Veh, CORT125281 on BAT activity in vivo. Additional partial agonistic activities of RU486 (as evident from reduced NE-induced UCP-1 expression in RU486-treated brown adipocytes in vitro, Fig. 2D ) may also explain the lower BAT-activating capacity of RU486.
In our study, we observed disturbed corticosterone rhythmicity upon HFD, which is in line with a previous study (31) . Nutrient sensors influence the peripheral clock (32) , and HFD was shown to alter diurnal patterns of leptin and insulin, as well as to reduce circadian patterns of clock genes in metabolic tissues (33) . Thus, the flattened corticosterone rhythm observed in our study could be a consequence of HFD-disturbed circadian rhythm, which is supported by the observation that the HFD-fed mice in our study eat throughout the whole day rather than mainly in the dark period (data not shown). Alternatively, HFD could influence the HPA axis and its hormones directly, as decreased 11b-HSD1 expression (which converts inactive into active GC) and altered corticotropin-releasing hormone and GR expression in the paraventricular nucleus were observed upon HFD feeding (31) . Fatty acids were also shown to regulate circulating corticosterone levels, and fatty acid sensors are known to be present in the hypothalamus (34) . FFA-lowering strategies (e.g., insulin administration) were shown to increase plasma ACTH and corticosterone levels (35) , and based on this, the decreased plasma FFA levels upon CORT125281 treatment could contribute to the restored corticosterone rhythmicity observed in our study. In addition, the lack of peripheral negative GC feedback on the HPA axis, due to the continuous presence of CORT125281, could contribute to the restored corticosterone rhythmicity. Although acute RU486 treatment can interfere with GR-mediated negative feedback and disinhibit the HPA axis (36) , in the present setting (continuous administration of high dose via the food), both corticosterone levels and adrenal weights were strongly reduced, suggesting suppression of ACTH release rather than classic disinhibition.
Although the reduced plasma lipids upon CORT125281 treatment can partially be attributed to enhanced BAT activity, it seems likely that enhanced lipid uptake by the liver is also involved. HFD induces hepatic expression of the cellular fatty acid transporter CD36 (37) . CD36 mediates hepatic lipid uptake and is critically involved in the pathogenesis of liver steatosis as its upregulation induces lipid accumulation in the liver (38) , and hepatic deletion of CD36 prevents this (39) . Both endogenous GC (14, 40) and synthetic GC agonists (41, 42) have been shown to increase hepatic CD36 expression, thereby aggravating liver steatosis (14) . Vice versa, GR knockout decreases hepatic CD36 expression and subsequently lowers liver lipids (43) . Surprisingly, treatment with CORT125281 and RU486 also increased hepatic Cd36 expression, which is likely attributed to activation of the xenobiotic sensor PXR (44) . This subsequently enhances fatty acid uptake, resulting in lipid accumulation and enhanced liver weight in mice. Currently, it is unknown if CORT125281 induces similar hepatic lipid accumulation in humans. Remarkably, in our studies, RU486 treatment is not associated with lipid accumulation, whereas RU486 is a known PXR ligand (28) and enhanced hepatic Cd36 and Cyp3a11 expression. This suggests additional lipid-lowering activities of RU486 (e.g., very-low-density lipoprotein production, b-oxidation) that prevent hepatic lipid uptake and accumulation and the development of steatosis. The differential effects of RU486 and CORT125281 may therefore be a consequence of the partial agonistic features of RU486 that are lacking in CORT125281.
To date, the utility of GR antagonists could be further improved for the treatment of metabolic disease. Based on our current study, GR antagonism with RU486 affects only body weight and fat mass but does not display additional beneficial metabolic activities, whereas the potential of CORT125281 may be limited due to adverse liver steatosis-inducing effects that we observe in mice. This may call for GR ligands that selectively act on BAT or that exhibit mixed agonistic and antagonistic features (45) (46) (47) (48) , to exploit the beneficial metabolic effects of both GR agonism and GR antagonism.
